Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
ONC filing a Form 144 reporting a proposed sale of 4,940 ADS by John Oyler on 06/08/2026. The excerpt shows the ADS relate to restricted stock vesting under a registered plan with a vesting date of 06/10/2026. The broker listed is Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York.
BeOne Medicines Ltd. held its 2026 annual general meeting, where shareholders approved all 20 proposals, including financial statements, director elections and compensation items under Swiss law.
Investors approved the Fifth Amended and Restated 2016 Share Option and Incentive Plan, increasing the shares available for awards by 75,400,000 ordinary shares, and the Sixth Amended and Restated 2018 Employee Share Purchase Plan, adding a further 3,250,000 ordinary shares for employee purchases. Shareholders re-elected John V. Oyler as chairman, refreshed the board and compensation committee, and ratified Ernst & Young entities as auditors.
They also granted a general mandate allowing the board to issue up to 20% of issued shares and a separate mandate to repurchase up to 10% of ordinary shares (excluding certain categories). A Connected Person Placing Authorization was approved, permitting allocations to Amgen Inc. to maintain its ownership percentage in future offerings.
BeOne Medicines Ltd. Principal Accounting Officer Titus B. Ball reported routine tax-related share sales. On June 8, 2026, he sold a total of 136 American Depositary Shares of BeOne Medicines in open-market transactions at weighted average prices of about $271.06 and $272.08. Footnotes state these sales were required under a mandatory tax withholding provision tied to the vesting of a previously granted restricted share unit award. Following these transactions, Ball reported direct ownership of 70,629 Ordinary Shares of BeOne Medicines.
BeOne Medicines Ltd. reported that SVP and General Counsel Henry Lee Chan disposed of American Depositary Shares mainly to satisfy tax obligations tied to vesting equity awards. On June 8, 2026, he sold a total of 871 American Depositary Shares in open-market transactions at weighted average prices around $270–$271 per ADS, pursuant to a mandatory tax withholding provision in his restricted share unit agreement.
Each American Depositary Share represents 13 Ordinary Shares. After these transactions, he continued to hold 307,047 Ordinary Shares directly, indicating he retains a substantial equity position in the company while using a portion of vested shares to cover tax requirements.
BeOne Medicines Ltd. executive Wang Lai, President and Global Head of R&D, reported selling 1,367 American Depositary Shares (ADS) on June 8, 2026 at weighted average prices around $269–$271. Each ADS represents 13 ordinary shares.
The sale was carried out under a mandatory tax withholding provision linked to the vesting of a restricted share unit award, rather than a discretionary open-market sale. Following these transactions, Wang Lai holds 1,601,288 ordinary shares directly and has additional indirect interests through entities and participation in an RMB employee share plan, with certain interests disclaimed as beneficial ownership under Section 16.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported selling 1,484 American Depositary Shares on June 8, 2026 in open-market transactions at prices of $270.55 and a weighted average of $269.3325 per ADS. According to the filing, the sale was effected under a mandatory tax withholding provision tied to the vesting of a restricted share unit award granted to him.
Following these transactions, he holds 40 American Depositary Shares directly, 4,000 American Depositary Shares indirectly through his wife, and 1,197,713 ordinary shares, which include 481 ordinary shares acquired through the company’s 2018 Employee Share Purchase Plan. Each ADS represents 13 ordinary shares.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported tax-related transactions in American Depositary Shares (ADSs). On June 8, 2026, a total of 4,940 ADSs were sold at weighted average prices of about $270–$271 per ADS. A footnote explains the sale was carried out under a mandatory tax withholding provision connected to the vesting of a previously granted restricted share unit award, rather than a discretionary open-market sale. Each ADS represents 13 Ordinary Shares. Following these transactions, Oyler held no ADSs directly, but continued to have substantial Ordinary Share holdings directly and through various trusts and entities, some of which he disclaims beneficial ownership in the footnotes.
The issuer reported a proposed sale of ADS securities on NASDAQ, filed on 06/08/2026. The filing lists 36,900.64 ADS and references a 06/05/2026 transaction date tied to Restricted Stock Vesting Under a Registered Plan.
ONC submitted a Form 144 notice indicating 871 ADS referenced under its securities information and a restricted stock vesting event on 06/05/2026. The excerpt lists three recent ADS dispositions: 332 ADS on 05/13/2026 for $103,159.04, 332 ADS on 04/08/2026 for $103,447.88, and 341 ADS on 03/11/2026 for $102,300.00.
The issuer reported a Form 144 notice for 1,367 ADS dated 06/05/2026, tied to restricted stock vesting under a registered plan. The form lists Morgan Stanley Smith Barney LLC as the broker and shows transaction details including an amount 368,246.83 and a reference number 54,885,669.